Table 1.

Patient characteristics and response

Patient no.Dose cohort, mg/m2Gender/ageECOG PSTumor typeTumor siteTumor diameter,a cmNumber of cyclesBest response,b (RECIST)TTP,b dTumor markers
01-0145F/490Ocular melanomaLiver4.07SD57
02-0145F/461Ovarian neuroendocrine carcinomaLiver6.33PDCA125 increase
5.6
2.6
3.7
02-0245F/620Ovarian papillary adenocarcinomaBladder3.211SD121CA125 stable
2.8
Pelvic node3
01-0254M/560Renal cell carcinomaMuscle5.30c
02-0354F/610Ovarian serous adenocarcinomaPelvic mass8.728SD373CA125 responsed
02-0454M/720Colon adenocarcinomaLiver85PDCEA decrease
02-0554F/500Colon adenocarcinomaLiver7.510SD105
01-0363F/401MelanomaSubcutaneous node4.63PD
01-0463F/441MelanomaLiver3.410SD57
01-0563F/511Adenocarcinoma of breastAxillar node4.67SD93
02-0663M/521Adenocarcinoma of rectumLiver13.41SD18
11.1
3.4
02-0863M/801Colon adenocarcinomaLiver5.48SD56
02-0963F/282Hemangiosarcoma of breastOvarian mass6.91NE
02-1063M/601Adenocarcinoma of rectumSacral mass9.24SD44
02-1263F/631Ovarian serous adenocarcinomaLiver4.03PD

Abbreviations: CA125, cancer antigen 125; CEA, carcinoembryonic antigen; ECOG PS, Eastern Cooperative Oncology Group performance score; NE, not evaluable; PD, progressive disease; SD, stable disease; TTP, time to progression.

  • aTumor diameter was measured by DCE-MRI.

  • bBest response and TTP were determined by computed tomographic scan.

  • cDay 1 treatment only.

  • dAccording to GCIG criteria.